全文获取类型
收费全文 | 4633篇 |
免费 | 285篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 101篇 |
妇产科学 | 88篇 |
基础医学 | 907篇 |
口腔科学 | 102篇 |
临床医学 | 346篇 |
内科学 | 1017篇 |
皮肤病学 | 104篇 |
神经病学 | 332篇 |
特种医学 | 114篇 |
外科学 | 684篇 |
综合类 | 21篇 |
一般理论 | 3篇 |
预防医学 | 261篇 |
眼科学 | 160篇 |
药学 | 323篇 |
中国医学 | 10篇 |
肿瘤学 | 324篇 |
出版年
2023年 | 48篇 |
2022年 | 139篇 |
2021年 | 181篇 |
2020年 | 104篇 |
2019年 | 121篇 |
2018年 | 149篇 |
2017年 | 103篇 |
2016年 | 109篇 |
2015年 | 146篇 |
2014年 | 154篇 |
2013年 | 182篇 |
2012年 | 280篇 |
2011年 | 271篇 |
2010年 | 184篇 |
2009年 | 138篇 |
2008年 | 270篇 |
2007年 | 249篇 |
2006年 | 237篇 |
2005年 | 243篇 |
2004年 | 205篇 |
2003年 | 194篇 |
2002年 | 163篇 |
2001年 | 48篇 |
2000年 | 40篇 |
1999年 | 50篇 |
1998年 | 39篇 |
1997年 | 35篇 |
1996年 | 26篇 |
1995年 | 21篇 |
1992年 | 37篇 |
1991年 | 37篇 |
1990年 | 47篇 |
1989年 | 56篇 |
1988年 | 42篇 |
1987年 | 58篇 |
1986年 | 37篇 |
1985年 | 57篇 |
1984年 | 33篇 |
1983年 | 23篇 |
1979年 | 26篇 |
1978年 | 25篇 |
1976年 | 24篇 |
1975年 | 26篇 |
1973年 | 34篇 |
1972年 | 18篇 |
1971年 | 29篇 |
1970年 | 25篇 |
1969年 | 21篇 |
1967年 | 24篇 |
1966年 | 19篇 |
排序方式: 共有4945条查询结果,搜索用时 31 毫秒
141.
142.
Juliet Emamaullee Lisa Tenorio Sara Khan Chante Butler Susan Kim Reginald Tucker-Seeley Yong Kwon James Shapiro Sanjiv Saigal Linda Sher Yuri Genyk 《Clinical transplantation》2020,34(11):e14073
Living donor liver transplantation (LDLT) has increased availability of liver transplantation, particularly in countries with limited access to deceased organ donors. It is unclear how individual countries address the financial impact of donation for potential living donors. Herein, living liver donor financial supports were examined, focusing on countries performing ≥10 LDLT per year in the World Health Organization Transplant Observatory. Categories included health insurance coverage, reimbursement of lost wages, employment protection, and other incentives designed to promote living liver donation. Overall, 26 countries have some form of asssistance in removing disincentives to ease the financial burden of living donation, ranging from childcare, accommodations, meals, and travel reimbursement, to coverage of medical complications post-donation. Most countries provide donation-related medical coverage. Fourteen provide reimbursement of lost wages and/or paid time off. Several unique programs were designed to incentivize living donation, including free entry to museums and observatories, parking and airline discounts, and exemptions on mortgages and medical deductibles. This study highlights the broad range of programs designed to support living liver donation in high-volume LDLT countries. The data collected in this study can provide a framework for other nations to propose and implement ethical reimbursement and incentivization for living liver donors. 相似文献
143.
144.
Miguel A. Lanaspa Takuji Ishimoto Christina Cicerchi Yoshifuru Tamura Carlos A. Roncal-Jimenez Wei Chen Katsuyuki Tanabe Ana Andres-Hernando David J. Orlicky Esteban Finol Shinichiro Inaba Nanxing Li Christopher J. Rivard Tomoki Kosugi Laura G. Sanchez-Lozada J. Mark Petrash Yuri Y. Sautin A. Ahsan Ejaz Wataru Kitagawa Gabriela E. Garcia David T. Bonthron Aruna Asipu Christine P. Diggle Bernardo Rodriguez-Iturbe Takahiko Nakagawa Richard J. Johnson 《Journal of the American Society of Nephrology : JASN》2014,25(11):2526-2538
Diabetes is associated with activation of the polyol pathway, in which glucose is converted to sorbitol by aldose reductase. Previous studies focused on the role of sorbitol in mediating diabetic complications. However, in the proximal tubule, sorbitol can be converted to fructose, which is then metabolized largely by fructokinase, also known as ketohexokinase, leading to ATP depletion, proinflammatory cytokine expression, and oxidative stress. We and others recently identified a potential deleterious role of dietary fructose in the generation of tubulointerstitial injury and the acceleration of CKD. In this study, we investigated the potential role of endogenous fructose production, as opposed to dietary fructose, and its metabolism through fructokinase in the development of diabetic nephropathy. Wild-type mice with streptozotocin-induced diabetes developed proteinuria, reduced GFR, and renal glomerular and proximal tubular injury. Increased renal expression of aldose reductase; elevated levels of renal sorbitol, fructose, and uric acid; and low levels of ATP confirmed activation of the fructokinase pathway. Furthermore, renal expression of inflammatory cytokines with macrophage infiltration was prominent. In contrast, diabetic fructokinase–deficient mice demonstrated significantly less proteinuria, renal dysfunction, renal injury, and inflammation. These studies identify fructokinase as a novel mediator of diabetic nephropathy and document a novel role for endogenous fructose production, or fructoneogenesis, in driving renal disease.Diabetic nephropathy is the most common kidney disease causing ESRD worldwide and also one of the most difficult diseases to treat. To date, treatment includes tight blood glucose and BP control and inhibition of the renin-angiotensin-aldosterone system. These efforts typically slow but do not arrest the progression of kidney disease.1 It is therefore imperative to better understand the mechanisms responsible for renal injury and to develop additional therapies.Recently, fructose has emerged as a potential nephrotoxin. Fructose-fed rats develop modest tubulointerstitial injury,2 and fructose supplementation accelerates renal disease in the remnant kidney model.3 While all studies to date have focused on dietary fructose as the source of fructose, fructose can also be generated from glucose in diabetes because of the activation of the polyol pathway in the proximal tubule. To date, no studies have examined the role of this endogenous fructose production or fructoneogenesis in driving diabetic nephropathy. Therefore, we tested the hypothesis that mice lacking fructokinase-ketohexokinase (khk−/−) show protection from diabetic nephropathy, even in the absence of dietary fructose, as a result of their inability to metabolize endogenously produced fructose. 相似文献
145.
Asuka Horie Kazuya Ishida Yuri Watanabe Kaito Shibata Yukiya Hashimoto 《Biopharmaceutics & drug disposition》2014,35(9):532-542
The aim of the present study was to investigate the membrane transport mechanisms of choline using human intestinal epithelial LS180 cells. The mRNA of choline transporter‐like proteins (CTLs) was expressed significantly in LS180 cells, and the rank order was CTL1 > CTL4 > CTL3 > CTL2 > CTL5. In contrast, the mRNA expression of other choline transporters, organic cation transporter (OCT) 1, OCT2 and high‐affinity choline transporter 1 (CHT1), was considerably lower in LS180 cells. Five mm unlabelled choline, hemicolinium‐3 and guanidine, but not tetraethylammonium, inhibited the cellular uptake of 100 µm choline in LS180 cells. The uptake of choline into LS180 cells was virtually Na+‐independent. The uptake of choline was significantly decreased by acidification of the extracellular pH; however, it was not increased by alkalization of the extracellular pH. In addition, both acidification and alkalization of intracellular pH decreased the uptake of choline, indicating that the choline uptake in LS180 cells is not stimulated by the outward H+ gradient. On the other hand, the uptake of choline was decreased by membrane depolarization along with increasing extracellular K+ concentration. In addition, the Na+‐independent uptake of choline was saturable, and the Km value was estimated to be 108 µm . These findings suggest that the uptake of choline into LS180 cells is membrane potential‐dependent, but not outward H+ gradient‐dependent. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
146.
147.
Kevin J. Makati Nitesh Sood Lawrence S. Lee Felix Yang Christian C. Shults David B. DeLurgio Juraj Melichercik Jaswinder S. Gill Riyaz A. Kaba Syed Ahsan Rukshen Weerasooriya Pragnesh Joshi Nicolas Lellouche Yuri Blaauw Konstantinos Zannis Frederic A. Sebag Andre Gauri Michael O. Zembala Jonathan S. Steinberg 《Heart rhythm》2021,18(2):303-312
148.
Ekaterina S. Prokudina Boris K. Kurbatov Konstantin V. Zavadovsky Alexander V. Vrublevsky Natalia V. Naryzhnaya Yuri B. Lishmanov Leonid N. Maslov Peter R. Oeltgen 《Current Cardiology Reviews》2021,17(2):188
The purpose of the review is the analysis of clinical and experimental data on the etiology and pathogenesis of takotsubo syndrome (TS). TS is characterized by contractile dysfunction, which usually affects the apical region of the heart without obstruction of coronary artery, moderate increase in myocardial necrosis markers, prolonged QTc interval (in 50% of patients), sometimes elevation of ST segment (in 19% of patients), increase N-Terminal Pro-B-Type Natriuretic Peptide level, microvascular dysfunction, sometimes spasm of the epicardial coronary arteries (in 10% of patients), myocardial edema, and life-threatening ventricular arrhythmias (in 11% of patients). Stress cardiomyopathy is a rare disease, it is observed in 0.6 - 2.5% of patients with acute coronary syndrome. The occurrence of takotsubo syndrome is 9 times higher in women, who are aged 60-70 years old, than in men. The hospital mortality among patients with TS corresponds to 3.5% - 12%. Physical or emotional stress do not precede disease in all patients with TS. Most of patients with TS have neurological or mental illnesses. The level of catecholamines is increased in patients with TS, therefore, the occurrence of TS is associated with excessive activation of the adrenergic system. The negative inotropic effect of catecholamines is associated with the activation of β2 adrenergic receptors. An important role of the adrenergic system in the pathogenesis of TS is confirmed by studies which were performed using 125I-metaiodobenzylguanidine (125I -MIBG). TS causes edema and inflammation of the myocardium. The inflammatory response in TS is systemic. TS causes impaired coronary microcirculation and reduces coronary reserve. There is a reason to believe that an increase in blood viscosity may play an important role in the pathogenesis of microcirculatory dysfunction in patients with TS. Epicardial coronary artery spasm is not obligatory for the occurrence of TS. Cortisol, endothelin-1 and microRNAs are challengers for the role of TS triggers. A decrease in estrogen levels is a factor contributing to the onset of TS. The central nervous system appears to play an important role in the pathogenesis of TS. 相似文献
149.
Yana V Kiseleva Sevak Z Antonyan Tatyana S Zharikova Kirill A Tupikin Dmitry V Kalinin Yuri O Zharikov 《World journal of hepatology》2021,13(3):270-290
The liver is a unique parenchymal organ with a regenerative capacity allowing it to restore up to 70% of its volume. Although knowledge of this phenomenon dates back to Greek mythology(the story of Prometheus), many aspects of liver regeneration are still not understood. A variety of different factors, including inflammatory cytokines, growth factors, and bile acids, promote liver regeneration and control the final size of the organ during typical regeneration, which is performed by mature hepatocytes, and during alternative regeneration, which is performed by recently identified resident stem cells called "hepatic progenitor cells". Hepatic progenitor cells drive liver regeneration when hepatocytes are unable to restore the liver mass, such as in cases of chronic injury or excessive acute injury. In liver maintenance, the body mass ratio is essential for homeostasis because the liver has numerous functions; therefore, a greater understanding of this process will lead to better control of liver injuries, improved transplantation of small grafts and the discovery of new methods for the treatment of liver diseases. The current review sheds light on the key molecular pathways and cells involved in typical and progenitor-dependent liver mass regeneration after various acute or chronic injuries. Subsequent studies and a better understanding of liver regeneration will lead to the development of new therapeutic methods for liver diseases. 相似文献
150.
Hai Thanh Pham Mitsuaki Ono Emilio Satoshi Hara Ha Thi Thu Nguyen Anh Tuan Dang Hang Thuy Do Taishi Komori Ikue Tosa Yuri Hazehara-Kunitomo Yuya Yoshioka Yasutaka Oida Kentaro Akiyama Takuo Kuboki 《Materials》2021,14(1)
Aging tissues present a progressive decline in homeostasis and regenerative capacities, which has been associated with degenerative changes in tissue-specific stem cells and stem cell niches. We hypothesized that amino acids could regulate the stem cell phenotype and differentiation ability of human bone marrow-derived mesenchymal stromal cells (hBMSCs). Thus, we performed a screening of 22 standard amino acids and found that D-tryptophan (10 μM) increased the number of cells positive for the early stem cell marker SSEA-4, and the gene expression levels of OCT-4, NANOG, and SOX-2 in hBMSCs. Comparison between D- and L-tryptophan isomers showed that the latter presents a stronger effect in inducing the mRNA levels of Oct-4 and Nanog, and in increasing the osteogenic differentiation of hBMSCs. On the other hand, L-tryptophan suppressed adipogenesis. The migration and colony-forming ability of hBMSCs were also enhanced by L-tryptophan treatment. In vivo experiments delivering L-tryptophan (50 mg/kg/day) by intraperitoneal injections for three weeks confirmed that L-tryptophan significantly increased the percentage of cells positive for SSEA-4, mRNA levels of Nanog and Oct-4, and the migration and colony-forming ability of mouse BMSCs. L-kynurenine, a major metabolite of L-tryptophan, also induced similar effects of L-tryptophan in enhancing stemness and osteogenic differentiation of BMSCs in vitro and in vivo, possibly indicating the involvement of the kynurenine pathway as the downstream signaling of L-tryptophan. Finally, since BMSCs migrate to the wound healing site to promote bone healing, surgical defects of 1 mm in diameter were created in mouse femur to evaluate bone formation after two weeks of L-tryptophan or L-kynurenine injection. Both L-tryptophan and L-kynurenine accelerated bone healing compared to the PBS-injected control group. In summary, L-tryptophan enhanced the stemness and osteoblastic differentiation of BMSCs and may be used as an essential factor to maintain the stem cell properties and accelerate bone healing and/or prevent bone loss. 相似文献